Evidence map›Paper›PMID 24797583›Full record

ArticleImmunology and cell biology2014

Phorbol myristate acetate, but not CD40L, induces the differentiation of CLL B cells into Ab-secreting cells.

Hussein Ghamlouch, Hakim Ouled-Haddou, Aude Guyart, Aline Regnier, Stéphanie Trudel, Jean-François Claisse, Vincent Fuentes, Bruno Royer, Jean-Pierre Marolleau, Brigitte Gubler

Open access · bronzeAbstract read
In one paragraph

Article in Immunology and cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Actovegin® reduces PMA-induced inflammation on human cells.European journal of applied physiology · 2020
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hussein GhamlouchEA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France.
Hakim Ouled-HaddouEA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France.
Aude GuyartEA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France.
Aline Regnier1] EA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France [2] Service d'Hématologie Clinique et Thérapie Cellulaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Stéphanie Trudel1] EA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France [2] Laboratoire d'Oncobiologie Moléculaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Jean-François ClaisseService d'Hématologie Clinique et Thérapie Cellulaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Vincent FuentesEA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France.
Bruno Royer1] EA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France [2] Service d'Hématologie Clinique et Thérapie Cellulaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Jean-Pierre Marolleau1] EA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France [2] Service d'Hématologie Clinique et Thérapie Cellulaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Brigitte Gubler1] EA4666, Laboratoire d'Immunologie, UFR de Médecine, Université de Picardie Jules Verne, Amiens, France [2] Laboratoire d'Oncobiologie Moléculaire, CHU d'Amiens, Avenue René Laënnec, Amiens, France.
Université de Picardie Jules Verne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigated the capacity of chronic lymphocytic leukemia (CLL) B cells to undergo terminal differentiation into Ig-secreting plasma cells in T cell-independent and T cell-dependent responses. We used a two-step model involving stimulation with phorbol myristate acetate (PMA) and CD40L, together with cytokines (PMA/c and CD40L/c), for 7 days. We describe immunophenotypic modifications, changes in the levels of mRNA and protein for transcription factors and morphological and functional events occurring during the differentiation of CLL B cells into antibody-secreting cells (ASCs). The induction of differentiation differed significantly between the CD40L/c and PMA/c culture systems. The PMA/c culture system allowed CLL B cells to differentiate into IgM-secreting cells with an immunophenotype and molecular profile resembling those of preplasmablasts. By contrast, CD40L/c-stimulated cells had a phenotype and morphology similar to those of activated B cells and resembling those of the CLL B cells residing in the lymph node and bone marrow. These data suggest that the CLL B cells are not frozen permanently at a stage of differentiation and are able to differentiate into ASCs as appropriate stimulation are provided. The data presented here raise questions about the molecular processes and stimulation required for CLL B-cell differentiation and about the inability of CD40 ligand to induce differentiation of the CLL B cells.

Indexed as

AgedAged, 80 and overAntibody FormationAntigens, SurfaceB-LymphocytesCD40 LigandCell DifferentiationCytokinesFemaleGene Expression Regulation, NeoplasticHumansImmunoglobulin MImmunophenotypingLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedAntigens, SurfaceCD40 LigandCytokinesImmunoglobulin MTetradecanoylphorbol Acetate

Identifiers

PMID24797583
PMCPMC4134517
OpenAlexW1969981731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.